DelveInsight Business Research LLP

(Nevada, Las Vegas, United States) DelveInsight’s“Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cryopyrin Associated Periodic Syndrome Pipeline Report

• Over 4+ companies and 4+ pipeline drugs in Craniopharyngioma are in various stages of development, and their anticipated acceptance in the Craniopharyngioma market would significantly increase market revenue.

• Leading Cryopyrin Associated Periodic Syndrome companies developing novel drug candidates to improve the Cryopyrin Associated Periodic Syndrome treatment landscape include Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, and many others.

• Promising Crispr Therapies pipeline therapies in various stages of development include ZYIL1, DFV890, Zunsemetinib, and many others

Cryopyrin Associated Periodic Syndrome Overview

Cryopyrin-associated periodic syndrome or syndromes, also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by ‘gain-of-function' mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome, and milder familial cold urticaria. Cryopyrin-Associated Autoinflammatory Syndromes is a group of illnesses related to defects in the protein cryopyrin (also called NLRP3). These diseases differ in the systems involved and in the severity of the disease. 

Discover more about the emerging Cryopyrin Associated Periodic Syndrome drugs @ Cryoprin Associated Periodic Syndrome Treatment Drugs

Cryopyrin Associated Periodic Syndrome Pipeline Therapies and Key Companies

ZYIL 1 : Zydus Cadila

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. It was found to be safe and well-tolerated in Phase I trials. Currently, it is in the Phase II stage of development to treat Cryopyrin-associated periodic syndromes.

DFV890: Novartis Pharmaceuticals

DFV 890 is an NLRP3 protein inhibitor being developed by Novartis. Currently, it is in Phase II stage of development to treat Cryopyrin-associated periodic syndromes.

Zunsemetinib: Aclaris Therapeutics

Zunsemetinib is an investigational oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor. This mechanism potentially leads to the inhibition of multiple cytokines, chemokines, matrix metalloproteases and other inflammatory signals. Key inflammatory cytokines driven by this mechanism include tumor necrosis factor α (TNFα) and interleukin-1α, -1β, -6, and -8 (IL1α, IL1β, IL6, and IL8). Aclaris is developing zunsemetinib as a potential treatment for RA and other immuno-inflammatory diseases. Currently, the drug is in the phase 2 stage of development for the treatment of Cryopyrin-associated periodic syndromes.

IZD334: Inflazome

IZD334 is an NLRP3 protein inhibitor. Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, and IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. The acquisition of Inflazome had given Roche full rights to the Inflazome portfolio.

Scope of the Cryopyrin Associated Periodic Syndrome Pipeline Report 

• Coverage: Global 

• Key Cryopyrin Associated Periodic Syndrome Companies: Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics, Mabpharm, and many others.

• Key Cryopyrin Associated Periodic Syndrome Pipeline Therapies: ZYIL1, DFV890, Zunsemetinib, and many others.

Find out more about the Cryoprin Associated Periodic Syndrome treatment options in development @ Cryoprin Associated Periodic Syndrome Clinical Trials

Table of Contents

1. Cryopyrin Associated Periodic Syndrome Introduction

2. Cryopyrin Associated Periodic Syndrome Executive Summary

3. Cryopyrin Associated Periodic Syndrome Overview

4. Cryopyrin Associated Periodic Syndrome Pipeline Therapeutics

5. Cryopyrin Associated Periodic Syndrome Late-Stage Products (Phase III)

6. Cryopyrin Associated Periodic Syndrome Mid-Stage Products (Phase  II)

7. Cryopyrin Associated Periodic Syndrome Early Stage Products (Phase  I/II)

8. Cryopyrin Associated Periodic Syndrome Preclinical Stage Products

9. Cryopyrin Associated Periodic Syndrome Discovery Stage Products

10. Cryopyrin Associated Periodic Syndrome Therapeutic Assessment

11. Cryopyrin Associated Periodic Syndrome Inactive Products

12. Cryopyrin Associated Periodic Syndrome Collaborations Assessment- Licensing / Partnering / Funding

13. Cryopyrin Associated Periodic Syndrome Unmet Needs

14. Cryoprin Associated Periodic Syndrome Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services